How Do Tirzepatide and Retatrutide Compare for Heart Protection in Diabetes?
Both tirzepatide and retatrutide improve cardiovascular risk markers in type 2 diabetes, but longer follow-up studies are needed to confirm long-term heart protection for both drugs.
Quick Facts
What This Study Found
Both tirzepatide and retatrutide improve glycemia, HbA1c, body weight, lipid profiles, blood pressure, and renal parameters in type 2 diabetes patients. Tirzepatide has recent proven cardiovascular benefits from dedicated outcomes trials. Retatrutide data is more limited, coming from earlier-phase trials. Both drugs show promising CV risk marker improvement, but standardized long-term follow-up is needed, especially for retatrutide.
Key Numbers
Review covered original RCTs from the last 10 years in adult human populations. Compared known data for retatrutide vs. tirzepatide.
How They Did This
Systematic review registered with PROSPERO (CRD42024507397). Included original RCTs from the last 10 years in English, conducted in adult human populations. Excluded cell/animal studies, case reports, reviews, and incomplete data. Seven studies assessed for bias using the Newcastle-Ottawa scale.
Why This Research Matters
The incretin therapy landscape is evolving rapidly from single GLP-1 agonists to dual (tirzepatide) and triple (retatrutide) receptor agonists. Understanding how these multi-target drugs compare for cardiovascular protection helps clinicians and patients make informed treatment choices as more options become available.
The Bigger Picture
The progression from single (GLP-1) to dual (GIP/GLP-1) to triple (GIP/GLP-1/glucagon) receptor agonists represents a major trend in diabetes pharmacology. Each additional target may add metabolic and cardiovascular benefits, but the evidence base needs to catch up.
What This Study Doesn't Tell Us
Only seven studies met inclusion criteria — limited evidence base especially for retatrutide. Heterogeneous study designs and follow-up periods. No direct head-to-head trials comparing tirzepatide to retatrutide. Long-term CV outcomes data not yet available for retatrutide. Assessment limited to metabolic surrogate markers rather than hard CV endpoints for retatrutide.
Questions This Raises
- ?Will retatrutide's triple-agonist mechanism provide stronger CV protection than tirzepatide?
- ?Are the cardiovascular benefits independent of metabolic improvements?
- ?How do these drugs compare for patients without diabetes who have CV risk?
Trust & Context
- Key Stat:
- Dual vs triple agonists Tirzepatide (dual GIP/GLP-1) has proven CV benefits; retatrutide (triple GIP/GLP-1/glucagon) shows promising markers but awaits dedicated CV outcomes trials
- Evidence Grade:
- Rated moderate: registered systematic review but limited by only 7 studies, heterogeneous designs, and lack of direct head-to-head comparison.
- Study Age:
- Published in 2024. Captures early evidence for both drugs, with tirzepatide data more mature than retatrutide.
- Original Title:
- Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 17(10) (2024)
- Authors:
- Salmen, Teodor(2), Potcovaru, Claudia-Gabriela, Bica, Ioana-Cristina, Giglio, Rosaria Vincenza, Patti, Angelo Maria, Stoica, Roxana-Adriana, Ciaccio, Marcello, El-Tanani, Mohamed, Janež, Andrej, Rizzo, Manfredi, Gherghiceanu, Florentina, Stoian, Anca Pantea
- Database ID:
- RPEP-09196
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Is tirzepatide good for the heart?
Yes — tirzepatide has recently proven cardiovascular benefits in dedicated outcomes trials, including improvements in blood sugar, weight, lipids, and blood pressure.
How does retatrutide compare to tirzepatide?
Retatrutide targets three receptors (GIP, GLP-1, and glucagon) versus tirzepatide's two. Early data shows promising metabolic benefits, but long-term cardiovascular outcomes data is not yet available.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09196APA
Salmen, Teodor; Potcovaru, Claudia-Gabriela; Bica, Ioana-Cristina; Giglio, Rosaria Vincenza; Patti, Angelo Maria; Stoica, Roxana-Adriana; Ciaccio, Marcello; El-Tanani, Mohamed; Janež, Andrej; Rizzo, Manfredi; Gherghiceanu, Florentina; Stoian, Anca Pantea. (2024). Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.. Pharmaceuticals (Basel, Switzerland), 17(10). https://doi.org/10.3390/ph17101322
MLA
Salmen, Teodor, et al. "Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.." Pharmaceuticals (Basel, 2024. https://doi.org/10.3390/ph17101322
RethinkPeptides
RethinkPeptides Research Database. "Evaluating the Impact of Novel Incretin Therapies on Cardiov..." RPEP-09196. Retrieved from https://rethinkpeptides.com/research/salmen-2024-evaluating-the-impact-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.